Spero Therapeutics, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2020 | $21.4M | $153.5M | $85.2M |
| FY2021 | $82.8M | $171.1M | $112.6M |
| FY2022 | $48.9M | $124.8M | $109.1M |
| FY2023 | $75.5M | $182.4M | $76.3M |
| FY2024 | $64.4M | $110.5M | $52.9M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2020 | $21.4M | $153.5M | $85.2M |
| FY2021 | $82.8M | $171.1M | $112.6M |
| FY2022 | $48.9M | $124.8M | $109.1M |
| FY2023 | $75.5M | $182.4M | $76.3M |
| FY2024 | $64.4M | $110.5M | $52.9M |